J&J Hit With $2.5M Verdict In 1st Philly Risperdal Trial

Law360, Philadelphia (February 24, 2015, 2:25 PM EST) -- A Philadelphia jury slapped a Johnson & Johnson unit with $2.5 million in damages on Tuesday in the first verdict over the antipsychotic drug Risperdal's connections to abnormal breast growth in males, finding the drugmaker failed to warn an autistic boy's parents and physicians of the risks.

The verdict came after a monthlong trial in the Philadelphia County Court of Common Pleas, in which the jury heard evidence that Janssen Pharmaceuticals Inc. had worked for years to obscure evidence that the drug was linked to growth...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.